Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Distribution Solutions Group, Inc. for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Group 1 - The investigation is focused on the possible legal issues surrounding Distribution Solutions Group, Inc. (NASDAQ: DSGR) [1] - Investors who lost money on Distribution Solutions Group, Inc. are encouraged to inquire about pursuing claims to recover their losses [1]

Core Viewpoint - The Trip.com class action lawsuit alleges that the company and its executives made misleading statements regarding regulatory risks associated with its monopolistic practices, leading to significant financial losses for investors during the specified class period [4][5]. Company Overview - Trip.com operates as a travel service provider, offering services such as accommodation reservations, transportation ticketing, packaged tours, in-destination services, and corporate travel management [3]. Allegations and Impact - The lawsuit claims that during the class period, Trip.com failed to disclose the regulatory risks it faced due to its monopolistic business activities [4]. - Following a Bloomberg article on January 14, 2026, which reported an antitrust investigation into Trip.com by Chinese authorities, the company's American Depositary Shares experienced a price drop of approximately 19% over two trading sessions [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Trip.com securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Corcept Therapeutics Incorporated due to significant losses following regulatory issues with the FDA [1][5]. Group 1: Investigation Background - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its new drug application for relacorilant, leading to a share price decline of approximately 50% [3]. - On January 30, 2026, a corrected CRL revealed that the FDA had previously informed Corcept of concerns regarding its clinical development program, resulting in another double-digit decline in share price [4]. Group 2: Legal and Investor Support - Johnson Fistel is assessing whether Corcept complied with federal securities laws, inviting affected investors to join the investigation [5]. - The firm offers no-cost consultations for investors who suffered losses from their investment in Corcept stock [2]. Group 3: Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, with a history of recovering significant amounts for clients [6][7].

Core Viewpoint - The Soleno Therapeutics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the safety and commercial viability of its product DCCR for treating hyperphagia in Prader-Willi syndrome patients [1][3]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its only commercial product being diazoxide choline extended-release tablets (DCCR) [2]. Allegations of the Lawsuit - The lawsuit claims that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [3]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [3]. Impact of External Reports - On August 15, 2025, a critical report by Scorpion Capital LLC led to a nearly 12% decline in Soleno's stock price over two trading days [4]. - Following a report of a patient death associated with DCCR on September 10, 2025, Soleno's stock price dropped approximately 19% over two trading days [5]. - The financial results reported on November 4, 2025, indicated a "disruption" in DCCR's launch trajectory, resulting in a further 27% decline in stock price [6]. Legal Process - Investors who purchased Soleno common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [7]. - The ability to share in any potential recovery from the lawsuit is not contingent upon serving as lead plaintiff [8]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [9].

Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly making materially false statements and failing to disclose adverse facts about its business and operations during the class period from February 25, 2025, to February 2, 2026 [4][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased PayPal common stock during the specified class period [2][7]. - Investors have until April 20, 2026, to file for lead plaintiff status [2][7]. - The complaint alleges that PayPal misrepresented its projected revenue outlook and growth potential, creating a false impression of stability and reliability [4][7]. Group 2: Stock Performance - PayPal's stock price dropped by $10.63, or 20.3%, closing at $41.70 per share on February 3, 2026, following a surprise leadership change and disappointing earnings report [5]. Group 3: Investor Actions - Investors can seek to be appointed as lead plaintiff representatives or choose to remain absent class members [6][9]. - Kessler Topaz Meltzer & Check, LLP offers free case evaluations and operates on a contingency fee basis [8][10].

Core Viewpoint - Smart Digital Group Limited (SDM) is facing a securities fraud class action lawsuit due to allegations of market manipulation and misleading statements made by the company's executives during the class period from May 5, 2025, to September 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit is initiated by shareholders who lost $1,000,000 or more and aims to appoint a lead plaintiff by the deadline of March 16, 2026 [1] - The complaint alleges that SDM's executives made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [1] - Specific allegations include the involvement of social media misinformation, insider trading, and the omission of risks related to market manipulation that could lead to trading suspensions by the SEC and NASDAQ [1] Group 2: Trading Activity - On September 26, 2025, NASDAQ temporarily halted trading of SDM stock due to volatility, with over 270,000 orders placed in a single minute, representing approximately 30% of the average daily volume [1] - Following the trading halt, SDM's stock price dropped to $1.85 per share, an 88% decrease from the previous day's closing price [1] - The SEC announced a temporary suspension of trading in SDM from September 29, 2025, to October 25, 2025, due to potential manipulation [1]

Core Viewpoint - Boston Scientific Corporation (BSX) is facing a securities fraud lawsuit due to disappointing financial results and misleading statements regarding its U.S. Electrophysiology (EP) segment growth [1] Financial Performance - On February 4, 2026, Boston Scientific reported fourth quarter and full year 2025 results, highlighting a decline in U.S. Electrophysiology sales and issuing fiscal 2026 guidance that fell below market expectations [1] - The company's stock price dropped by $16.12, or 17.6%, closing at $75.50 per share following the announcement [1] Lawsuit Details - The lawsuit alleges that Boston Scientific made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period from July 23, 2025, to February 3, 2026 [1] - Specific allegations include unsustainable growth rates in the U.S. EP segment, new competition affecting market share, and misleading statements regarding the company's growth trajectory and business prospects [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased common stock of monday.com Ltd. (NASDAQ: MNDY) during the specified Class Period from September 17, 2025, to February 6, 2026, due to alleged securities fraud [1]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false and/or misleading statements regarding monday.com's revenue expansion outlook, including decelerating growth, reduced expansion momentum, and extended sales cycles [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must move the Court by May 11, 2026, to represent other class members in the litigation [1]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [1]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [1]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and recognition in the field [1].

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with significant financial losses reported during the class period from November 5, 2025, to February 26, 2026 [1][3]. Company Overview - Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems aimed at utility-scale commercial and industrial applications [2]. Allegations of the Lawsuit - The lawsuit claims that Eos Energy made false or misleading statements and failed to disclose critical operational issues, including: - Inability to achieve production ramp-up and capacity utilization as per guidance [3]. - Battery line downtime exceeding industry norms and internal forecasts [3]. - Delays in automated bipolar production quality targets [3]. - Inadequate systems preventing accurate guidance and timely disclosures [3]. Financial Performance - On February 26, 2026, Eos Energy reported its fourth quarter and full year 2025 results, revealing: - Full year 2025 revenue of $114.2 million, significantly below the guidance of $150 million to $160 million [4]. - A gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million [4]. - An adjusted EBITDA loss of $219.1 million and a capacity milestone reached five weeks later than planned [4]. - Following this announcement, Eos Energy's stock price dropped by over 39% [4]. Legal Process - Investors who purchased Eos Energy securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [6].

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) for securities fraud, affecting shareholders who acquired stock between March 26, 2025, and November 4, 2026, with a deadline for lead plaintiff motions set for May 5, 2026 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that Soleno made materially false and misleading statements and failed to disclose significant safety concerns regarding its drug DCCR, which is used to treat hyperphagia in individuals with Prader-Willi syndrome [1] - The complaint highlights that the Phase 3 clinical trial for DCCR downplayed safety risks, including issues related to excess fluid retention [1] - The lawsuit claims that the drug posed greater safety risks than disclosed, leading to lower commercial viability and increased patient discontinuation rates [1] Stock Price Impact - Following the release of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27, or 11.98%, closing at $68.09 on August 18, 2025 [1] - After a patient death was reported on September 10, 2025, the stock price dropped by $13.49, or 19.21%, to close at $56.72 on September 11, 2025 [1] - On November 4, 2025, Soleno's third-quarter financial results indicated that the negative report had disrupted DCCR's launch, causing the stock to decline by $16.98, or 26.59%, to close at $46.87 on November 5, 2025 [1]